Completion of Phase 2B Trial of MIS416
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- Private Placement to raise Additional Working Capital
- Phase 2B Trial of MIS416 on Schedule to Complete April 2017
- IIL Panel Declines to Conduct Proceedings
- Appendix 4C - Dec 2016 Quarter Statement of Cashflows
- Response to Price Query
Later from Amplia Therapeutics
- Appendix 4C - March 17 Quarter Statement of Cash Flows
- Preliminary Final Report - Year Ended 31 March 2017
- FDA Clearance - MIS416 Investigational New Drug Application
- Top-Line Results for Trial of MIS416
- No Change in Trial Outcome Following Additional Analysis
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics